Acadia Pharmaceuticals Inc. (ACAD) — Analysis Summary
Acadia Pharmaceuticals Inc. (ACAD) has a market cap of $3.34B with year-over-year revenue growth of +11.9%. Net margin stands at 36.5%. The stock trades at a P/E ratio of 8.8.
Key Takeaways
- Revenue changed +11.9% year-over-year
- Net margin of 36.5%
- P/E ratio of 8.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, ACAD posted revenue growth of +11.9% and trades at a P/E of 8.8.
Acadia Pharmaceuticals Inc. (ACAD)
PREVIOUS CLOSE 2026-10-13 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Gross margin at 91.1% — verify: very few businesses sustain >90% gross margin outside pure software/IP
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise into making a difference for underserved neurological and rare disease communities around the world. It has two franchises in neurological and rare diseases. Its neurological disease franchise is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. FDA for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
798
Headquarters
SAN DIEGO, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.